PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS. (Q34760550)

4 August 2017

title

PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS. (English)

1 reference

4 August 2017

0 references

anti-retroviral agent

0 references

5

D M Gibb

1 reference

4 August 2017

M Sharland

1

1 reference

4 August 2017

G Castelli Gattinara di Zub

2

1 reference

4 August 2017

J Tomas Ramos

3

1 reference

4 August 2017

S Blanche

4

1 reference

4 August 2017

PENTA Steering Committee

6

1 reference

4 August 2017

publication date

1 July 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

3

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

215-226

1 reference

Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Diabetes unmasked by electric shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Variable use of therapeutic interventions for children with human immunodeficiency virus type 1 infection in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Evidence for a bimodal expression of clinical and biological symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

CD4+ and CD8+ T lymphocyte regeneration after anti-retroviral therapy in HIV-1-infected children and adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Immune control of HIV-1 after early treatment of acute infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Tolerance of efavirenz in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Adherence to medication regimens among children with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Genotypic characterization of human immunodeficiency virus type 1 isolated from vertically infected children with antiretroviral therapy experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

Combination Nucleoside Analog Reverse Transcriptase Inhibitor(s) Plus Nevirapine, Nelfinavir, or Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children: Week 24 Results of a Randomized Controlled Trial - PACTG 377

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00120.X

10.1046/J.1468-1293.2002.00120.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference